Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 p.Met774delinsTrpLeuVal (p.M774delinsWLV) ( ENST00000584601.5, ENST00000269571.10, ENST00000584450.5, ENST00000445658.6, ENST00000406381.6, ENST00000541774.5 )
ERBB2 p.Met774delinsTrpLeuVal (p.M774delinsWLV) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 )
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1894
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/818
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Dacomitinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
25899785
Drugs
Drug NameSensitivitySupported
DacomitinibSensitivitytrue